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Abstract
The complex between the proteins MDM2 and p53 is a promising drug target for cancer therapy. The residues 19–26 of p53
have been biochemically and structurally demonstrated to be a most critical region to maintain the association of MDM2
and p53. Variation of the amino acid sequence in this range obviously alters the binding affinity. Surprisingly, suitable
substitutions contiguous to this region of the p53 peptides can yield tightly binding peptides. The peptide variants may
differ by a single residue that vary little in their structural conformations and yet are characterized by large differences in
their binding affinities. In this study a systematic analysis into the role of single C-terminal mutations of a 12 residue
fragment of the p53 transactivation domain (TD) and an equivalent phage optimized peptide (12/1) were undertaken to
elucidate their mechanistic and thermodynamic differences in interacting with the N-terminal of MDM2. The experimental
results together with atomistically detailed dynamics simulations provide insight into the principles that govern peptide
design protocols with regard to protein-protein interactions and peptidomimetic design.
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Introduction
The tumour suppressor protein p53 is a transcription factor that
plays an essential role in guarding the cell in response to a variety of
stress signals through induction of cell cycle arrest, apoptosis or
senescence [1,2]. The activity of p53 is regulated by the E3-ubiquitin
ligaseMDM2.MDM2inhibitsp53bypreventingitsinteractionwith
the general transcription machinery and targeting it for ubiquitin-
mediated degradation. MDM2 interacts with p53 through at least
two regions: the N-terminus of p53 interacts with the N-terminal
domain of MDM2 and the DNA-binding domain of p53 interacts
with the acidic domain of MDM2 [3,4]. MDM2 is overexpressed in
many cancers, and is thought to be one of the primary causes of the
inactivation of the p53 networkinp53 wild type tumours[1]. In such
cases, disruption of the MDM2:p53 interaction has been shown to
stabilize andactivate thetranscriptional activityofp53 leading tocell
death or to G1/G2 cell cycle arrest [5,6].
The molecular interaction of the binding of the MDM2 N-
terminal domain to the p53 N-terminus (TA domain) is well
understood. Several high-resolution crystal and NMR structures in
complex with a variety of peptides and small molecules have been
elucidated [7,8]. These structural studies indicate that the residues
F19, W23 and L26 of the TA domain of p53 are critical for binding
to MDM2. Indeed most peptides, peptidomimetics and small
molecules that have been developed have indeed emerged as a
result of mimicking these interactions. However, it has been known
for some time that the other residues in this sequence, such as the C-
terminal residues, also modulate affinity [9]. Zondlo et al.
hypothesized that this may originate in the ability of these regions
to adopt a helical motif [10]. They found that the P27S substitution
in a peptide corresponding to residues 12–30 of the WT p53
sequence gave rise to ,200 fold improvement over the wild type
sequence in the Kd (dissociation constant) of binding to the N-
terminal domain of MDM2. CD and NMR suggested that the P27S
substitution appeared to increase the helical propensity of the
peptide. Computer simulations further complemented these findings
and additionally demonstrated that this interaction can originate in
multiple and distinct conformations of the peptide which include
both partly extended and helical motifs at the C-terminal end [11].
More recently, several phage derived peptides have been
derived and characterized with Kds that are of the same order
of magnitude as that reported by Zondlo et al. [10] Of these
peptides, two have either a T or S substitution in the P27 position,
and further structural characterization revealed that their C-
termini are in an extended a-helical conformation when bound to
MDM2 [12,13] in contrast to the extended form of the wild type
p53 peptide complexed with MDM2 [14]. These high affinity
peptides differ in their overall amino acid composition and so it is
hard to distill out the contributions from individual amino acids. In
contrast, we now show, through a combination of biophysical and
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sharing  data and materials.molecular dynamics simulation methods that the binding affinities
of two different MDM2 binding peptides can be further
modulated by several orders of magnitude by just single amino
acid substitutions. These changes lie at the C-terminus of the
peptide and what is surprising is the observation that these
peptides interact with MDM2 via two distinctive thermodynamic
mechanisms. The observations made in this study should aid in the
design of high affinity peptides. Coupled with emerging techniques
in delivering peptides into cells, e.g. cell penetrating peptides or
stapling, our observations should further aid the development of
peptides into clinical leads.
Materials and Methods
Peptides synthesis
All Fmoc-protected amino acids, Hydroxybenzotriazole
(HOBt), O-Benzotriazole-N,N,N9,N9-tetramethyl-uronium-hexa-
fluoro-phosphate (HBTU) and Rink amide resin were purchased
from Novabiochem (Germany). Trifluoroacetic acid (TFA) and
anhydrous ethyl ether was purchased from Sigma Aldrich (USA).
Dichloromethane (DCM), Diisopropylethylamine (DIPEA), N,N-
Dimethylformamide (DMF), piperidine and HPLC grade aceto-
nitrile were obtained from Merck (Germany).
Peptide amides were synthesized using a CEM Liberty (USA)
automated microwave peptide synthesizer on Rink amide resin.
All the peptides had their C-termini amidated. Fmoc deprotection
was performed using 20% piperidine in DMF (v/v) at 75uC for
5 minutes at 40 W. Amino acid coupling reactions were
performed in 5-fold molar excess of Fmoc-protected amino acids
dissolved in DMF with activating reagents HBTU:HOBt:DI-
PEA:amino acid (0.9:1:2:1 equivalents). Coupling reactions were
conducted over 10 minutes at 40 W and 75uC. Cleavage was
performed using 5 ml of cleavage solution TFA:water (95:5 v/v)
for 30 min at 40uC. Filtration was carried out and the resin was
washed thrice with DCM to obtain the filtrate. The filtrate was
concentrated under low-pressure centrifugal evaporation and the
crude peptides were precipitated using ice-cold anhydrous diethyl
ether. HPLC purification of peptide was performed using a Waters
X-bridge C18 column (19 mm diameter, 150 mm length) at
215 nm wavelength. Separation was achieved by gradient elution
of 25 to 45% solvent B (solvent A=0.1% TFA in water; solvent
B=0.1% TFA in acetonitrile) at a flow rate of 5 ml/min.
Molecular mass analysis was performed using Applied Biosystems
Mariner Mass Spectrometer (USA) with electrospray ionization.
Expression and purification of MDM2
DNA encoding residues Q18 to N125 of HDM2 were cloned as
a NdeI/BamHI fragment into pET19b (Novagen). Recombinant
clones carrying the correct insert were identified by DNA
sequencing. Plasmid from the identified clone was introduced into
E. coli BL21(DE3) and protein production in LB medium was
induced with IPTG (1 mM) when the cell density reached OD600
between 0.4 and 0.6. Induced cells were grown at room
temperature for 5 h, harvested, and then resuspended in buffer
A (50 mM Tris pH 8.0, 10% sucrose). After cell disruption and
centrifugation, supernatant was loaded onto a Ni-nitrilotriacetic
acid (NTA) column and washed with 5 column volumes of 0.3 M
NaCl, 50 mM Tris-HCl pH 8.0, 1 mM DTT. Hexahistidine
tagged MDM2 (18–125) was eluted with a 1 M imidazole linear
gradient. The protein was further purified by cation-exchange
chromatography (Pharmacia Mono S 5/5, 1 ml/min, 50 mM
Tris-HCl pH 7.0, 1 mM DTT) with a 1 M NaCl gradient. Protein
concentration was determined using A280 with an extinction
coefficient of 10430 M
21 cm
21.
Isothermal Titration Calorimetry (ITC)
ITC experiments were conducted in a VP-ITC Unit (MicroCal,
Northampton, MA). In a typical ITC experiment, 10 or 20 mMo f
MDM2 was loaded in the cell with 100 or 200 mM of peptide in
the titrating syringe, depending on the binding affinities of
compounds. All titrations were carried out in 1% DMSO.
MDM2 was dialysed into Phosphate Buffered Saline (2.7 mM
KCL and 137 mM NaCL, pH 7.4) with 0.05% TWEEN20 using
SLIDE-A-LYZER (Pierce) cassettes with a MWCO of 3000. All
peptides used were weighed out as solids and dissolved in DMSO.
The stock peptide solutions were diluted to their working
concentrations in the buffer used for dialysis of the protein.
DMSO was carefully added to the MDM2 solution in the VP-ITC
cell to buffer match it to the peptide solution. The titration
experiments were performed at 20uC with an initial 2 ml injection
with duration of 4 s, followed by 28 10 ml injections with a
duration of 7.1 s. The spacing between each injection was 150 s.
The stirring speed during the titration was 290 rpm. Data was
analyzed using Microcal Origin software by fitting to a single-site
binding model. Correction for the enthalpy of ligand dilution was
carried out by subtracting a linear fit from the last three data
points of the titration, after the interaction had reached saturation.
Circular Dichroism (CD)
CD was measured on a JASCO J-810 spectropolarimeter and
spectra were recorded in a 1 cm quartz cuvette (Helmer) in 5 mM
sodium phosphate buffer (pH 7.0). Far UV CD spectra were
recorded from 260 to 195 nm at a peptide concentration of
12.5 mM. The CD signal was converted to Delta Epsilons (De). CD
spectra were recorded at a data pitch of 0.2 nm at 50 nm/min, a
response time of 2 s and the bandwidth set at 2 nM.
Computer simulations
The crystal structure (PDB code 1YCR) of the complex between
MDM2 (residues 25–109) and a p53 peptide (residues 17–29) was
used as a template to model the complexes studied [14]. The
sequence of the 12/1 peptide was M1PRFMDYWEGLN12 and
the equivalent sequence in p53 is Q16ETFSDLWKLLP27. The
crystal structure (1YCR) of the complex between p53 and MDM2
does not contain the coordinates of the residue Q16. These were
modeled using CHARMM22 parameters [15]. The residue E28
and N29 were not included. The final complex between the
MDM2 and the 12 residue p53 peptide is referred to as p53WT
hereafter. This was also used to construct the complexes between
MDM2 and mutant p53 peptides resulting in P27S (p53Ser), P27A
(p53Ala), P27T (p53Thr) and P27N (p53Asn). The same protocol
was used to construct the MDM2-12/1 complex and its variants,
wild type (12/1), N12S (12/1Ser), N12A (12/1Ala), N12T (12/
1Thr), N12P (12/1Pro); the amino acid substitution of A, T and S
were made to the C-terminal ‘Asn’ which is equivalent to the
terminal Pro in the p53WT sequence. Patches were applied to
both ends of the peptides, with the N-terminus acetylated and the
C-terminus amidated.
Each complexwassolvated usinga box ofTIP3Pwatermolecules
[16], maintaining a minimum thickness of a water layer of 9 A ˚. The
net charge of the systems was neutralized by adding counter-ions
(Cl
2). After a brief energy minimization, the systems were subject to
molecular dynamics (MD) simulations that included an initial
heating to 300 K, followed by equilibrationunder constant pressure
and temperatureconditions (NPT). Finally, MDwasrunat constant
temperature and volume conditions (NVT) for 20 ns for each
system, leading to a combined simulation time of ,200 ns; the
20 ns timescale was chosen based on our earlier work on this
complex which has successfully reproduced experimental data [17].
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electrostatics and a 12 A ˚ cutoff was applied for short ranged non-
bonded interactions. SHAKE [18] was applied to freeze the
vibrations of bonds involving hydrogen atoms. The figures
(molecular structures) were prepared using Pymol [19] while the
movies were prepared using VMD [20].
Results
Single amino acid substitutions dramatically increase the
affinity of the MDM2 binding peptides
The p53WT peptide, as determined from ITC studies (see
Figure 1 and Table 1), has a Kd of 1543.21689.97 nM. The p53
derivative set of peptides displayed substantially stronger binding
to hexahistidine tagged MDM2 (18–125) compared to the original
peptide, with Kds ranging from ,13-fold to 36 fold lower than for
the wild type sequence. The p53Thr peptide was the most potent
peptide, with a Kd of 38.7667.43 nM. All three derivative
peptides (see Table 1) had Kds significantly lower than that of
racemic Nutlin (Kd was determined to be 201.61660.85 nM). The
12/1 peptide binds to MDM2 with a Kd of 239.81653.79 nM
which is ,6.5 fold lower than that of the p53WT peptide and is
similar to the Kd of racemic Nutlin (Table 1). Again all three
amino acid changes increased the potency of the peptide with 12/
1Ser and 12/1Thr having the lowest apparent Kdso f
18.8365.03 nM and 22.8864.21 nM respectively. Compared to
the equivalent substitutions in the p53 derived peptides, the 12/1
derived peptides do not improve binding as dramatically when
compared to their parent peptide. However when the equivalent
changes are compared to each other, the 12/1 derived peptides
have lower apparent Kd values than their p53 counterparts. The
12/1Ser peptide has a Kd value that is ,4 fold lower that the
p53Ser while the other two other peptides in the set are , two-fold
lower in their Kd than their equivalent p53-derived peptides.
A further set of peptides were designed to see if the Asn residue
located at the C-terminus of the 12/1 peptide would lead to an
Figure 1. Binding Isotherms of MDM2 with the MDM2 interacting peptides. Isothermal Calorimetry titrations of selected MDM2 binding
peptides against MDM2.
doi:10.1371/journal.pone.0024122.g001
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replace the Pro residue. The resultant p53Asn residue bound
MDM2 with an apparent Kd of ,168.0769.24 nM which is very
similar to the apparent Kd of the 12/1 peptide of
239.81653.79 nM. However if the Asn C-terminal residue of
the 12/1 peptide is changed to Pro there is no significant change in
the Kd of the new peptide compared to the parent peptide. This
perplexing result indicates a subtle difference in the modes of
interaction with MDM2 between the 12/1 and p53 based families
of peptides.
The two groups of peptides vary in the thermodynamics of their
interactions with MDM2. The p53 family members have a
DHbinding that ranges from 24.8 kcal/mol to 29.7 kcal/mol
(Table 1), whilst for the 12/1 peptide group it ranges between
27.8 kcal/mol and 210.8 kcal/mol (Table 1). The interaction of
the members of the 12/1 family of peptides is primarily
enthalpically driven compared to the p53 group, which have a
more favorable entropic component. Interestingly the p53Asn
peptide departs from this observation as it has the largest binding
enthalpy of the p53 based peptides and an unfavourable entropic
component. Also 12/1Pro has the most unfavourable entropic
component out of the 12/1 peptides. The Ser, Thr and Ala
modifications in the p53 family display a substantial increase in
affinity compared to the parent p53WT because of entropic
stabilizations. A similar mechanism underlies the Ser and Thr
mutants of the 12/1 peptides. However the Ala modification in
12/1 leads to a big increase in the enthalpy and hence affinity for
MDM2.
CD studies reveal increased helicity in p53 derivative
peptides compared to the 12/1 derivative peptides
To investigate the molecular basis for the observed increase in
affinity of the p53 and 12/1 derivative peptides we first focused on
their conformational states in solution for which we carried out
CD spectroscopic studies. The CD spectra of p53WT when
compared to the CD spectra of p53Ser (Figure 2A) shows that the
minima of the CD signal for the latter had undergone a small red
shift (202 nm) in comparison to the p53WT (197 nm); it also
exhibited a significant increase in the CD signal at 222 nm. These
spectra indicate that the p53Ser peptide is substantially more a-
helical than the p53WT peptide. Figure 2A also shows the CD
spectra of p53Thr and p53Ala when compared to the p53WT
peptide do not undergo a significant increase in the CD signal at
222 nm. However the spectra of the two daughter peptides do
show a small red shift (201 nm and 202 nm respectively) in the
minima and a decrease in the intensity of the CD signal observed
at the minima as well, suggestive of increased helicity when
compared to p53WT.
When the p53WT peptide and its derivatives are examined
under the same buffer conditions but with the addition of 30%
TFE, the CD spectra of the p53 derivative peptides show
significant helix formation with an increase in the intensity of
the CD signal at 206 nm and 222 nm and a sharp maxima at
195 nm (see Figure 2). Again the p53Ser peptide exhibits the
strongest helical signature, with the CD signal intensity reaching
25 and 24 at 208 nm and 222 nm respectively (see Figure 2).
This data confirms the observations by Zondlo et al [10] that the
Pro27Ser mutation does indeed increase helix formation in the
peptide. The CD signals of the other peptides are less intense. The
CD spectra of the p53WT in 30% TFE shows the features of the
p53Ala and p53Asn peptides in 5 mM Sodium Phosphate buffer,
with a small red shift of the CD spectra minima and a decrease in
its intensity (Figure 2). In general, the CD spectra suggest that the
p53-derivative peptides have a higher propensity to form an a-
helix than p53WT.
The CD spectra of the 12/1 family of peptides in Sodium
phosphate buffer pH 7.0 are very similar to that of the p53WT
peptide, and are typical of peptides in a coil formation exhibiting a
minima at 197 nm (see Figure 2). However, when the same CD
spectra are recorded with the addition of 30% TFE, all four
spectra undergo distinct changes. The 12/1 peptide undergoes a
slight red shift of the spectra minima (200 nm) and a decrease in
the signal intensity of the minima which is similar to that seen with
the p53WT peptide in 30%TFE. The 12/1 Ala peptide undergoes
a larger red shift (203 nm) whilst the 12/1Thr and 12/1Ser
peptides exhibit the red shift (205 nm and 204 nm respectively) as
well as an increase in the CD intensity at 222 nm (see Figure 2).
The 12/1Thr peptide has a slightly more intense CD signal at
222 nm and a greater red shift of its minima than the 12/1Ser,
indicating greater helical formation. From the CD spectra of the
12/1 family of peptides, the 12/1Ser and 12/1Thr peptides
display the greatest propensity for helix formation, followed by 12/
1Ala and finally the parent peptide 12/1.
The CD data indicates that the amino acid substitutions within
the p53WT sequence are clearly more a-helical inducing than
within the phage optimized sequence 12/1, with larger red shifts
being observed in buffer alone and in 30% TFE. Although both
families are helical to differing extents, it is clear that the effect
each substitution has is context dependent. These observations
suggest that the increased affinities of the peptides over their
parent peptides may originate in greater pre-structuring or pre-
organization into helical motifs prior to binding MDM2. And yet,
the fact that the 12/1 peptides are much less helical in nature than
the p53 derivative peptides also suggests that the increased affinity
of the 12/1 peptides compared to the p53 peptides will arise from
additional factors.
The spectra of the two peptides, p53Asn and 12/1Pro, where
the C-terminal residues have been exchanged, were also recorded.
The p53Asn peptide produced spectra remarkably similar to that
of p53Ser in both Sodium phosphate pH 7.0 buffer and with the
addition of 30% TFE, although it did exhibit a slightly greater red
shift in its minima in the absence of TFE. In contrast, the 12/1Pro,
Table 1. Calculated Kds and thermodynamic parameters for
the interactions between MDM2 and the derivative peptides.
Ligands
DG
(kCal/mol)
DH
(kCal/mol)
TDS
(kCal/mol)
Kd
(nM)
p53WT 27.7960.03 26.3460.07 1.45 1543.21689.97
p53 Ser 29.5460.08 25.0860.04 4.45 75.76610.45
p53Thr 29.9360.10 26.3360.05 3.57 38.7667.43
p53 Ala 29.3160.09 24.7960.05 4.54 112.11617.93
P53 Asn 29.076627 29.7160.04 20.62 168.0769.24
12/1 28.8760.12 29.3260.19 20.44 239.81653.79
12/1Ser 210.3560.14 27.8460.13 2.52 18.8365.03
12/1Thr 210.2460.10 28.2260.06 2.03 22.8864.21
12/1Ala 29.8260.12 210.8360.13 21.00 47.17611.07
12/1Pro 28.9460.09 210.3560.13 21.40 213.22636.59
Nutlin Racemic 28.9760.15 26.1060.16 2.88 201.61660.85
ITC determined values for enthalpy of binding, entropy of binding, peptide
dissociation constant and the binding free energy. The binding fee energy was
calculated from the Kd using DG=2RTlnKa. Experiments were carried out at
293 K.
doi:10.1371/journal.pone.0024122.t001
C-Terminal Modulation of MDM2 Binding Peptides
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e24122in both sets of conditions, possesses a random coil configuration
and shows negligible helix formation.
Computer simulations of the interactions between
MDM2 and the derivative peptides
The residues 16–27 of wild type (WT) p53 peptide
(Q16ETFSDLWKLLP27) are equivalent to residues 1–12 of the
12/1 peptide (M1PRFMDYWEGLN12). The template for
modeling of all complexes was the crystal structure of MDM2-
p53 (PDB code 1YCR; ([14])), where residues 19–25 of the p53
peptide form an a-helix, and the other residues are unstructured.
In all the p53 mutant peptides modeled, the region 19–25 was
assumed to be helical to begin with and rest of the peptide chain
(residue 16–18 and 26–27) had no defined secondary structure.
Similarly, for the 12/1 peptide and its mutants, residues 4–10
were modeled as a-helical, resembling closely the backbone of the
p53 peptide in the crystal structure, while the remainder of the
residues were unstructured, but shared a conformation similar to
that of the p53 peptide complexed to MDM2 in the crystal
structure. A general trend observed from the simulations was that
the last two C-terminal residues of the peptides undergo a
transition from an extended strand conformation to a helical
conformation within a few nanoseconds (see Movies S1). This
change in peptide conformation, coupled with the flipping of
Y100 (MDM2) towards the ligand binding pocket, creates a more
complementary fit for the peptide in the MDM2 binding pocket
as has been reported previously [11,13,21,22]. Without the
rotation of the Y100 side chain, the C-terminal residues in the
peptide would not make any specific contacts with MDM2. The
simulations show that the formation of a helical conformation at
the C-terminal is favoured and allows for better packing against
the surface of MDM2, except in the presence of Pro (see Figure 3).
The helical conformation is associated with intrahelical hydrogen
bonds (see Figure 4) that the last two residues form and also
appears to optimize the hydrophobic packing against the flipped
Y100 side chain. This flipping of the Y100 side chain is
additionally enthalpically favoured because it engages the
hydroxyl of the Y100 in hydrogen bonds with the peptide
backbone. Figure 3 shows that smaller side chains like Ser orient
towards the MDM2 peptide binding cleft whereas larger groups
like Asn point away from the binding cleft, towards K51. This
area of MDM2 is polar in nature and stabilizes the preferred
conformations of Asn and Ser. On the other hand the Ala side
chain is unable to form interactions in this polar pocket of
MDM2 in a manner that Ser/Thr can, and results in larger
fluctuations in this region (see Movies S1). The N-terminal ends
of the peptides are largely unstructured when bound to MDM2.
For p53WT, the interaction of E17 with K94 of MDM2 prevents
the formation of secondary structure in the region Q16-T18 of
the peptide even though the helical propensities of these residues
are high: Q16 (1.11), E2 (1.51), T (0.83), F(1.13). In a separate
study, this region has been shown to undergo a conformational
change to a helix, arising from long range electrostatic
interactions [23] and is indicative of the plasticity of the
underlying energy surface. In the case of 12/1, the E17 of
p53WT is substituted with Pro which prevents any major
Figure 2. CD spectra of MDM2 interacting peptides free in solution. (A) CD spectra of the peptides P53Ser, p53Thr, p53Ala, p53ASN and
p53WT in 5 mM Sodium Phosphate buffer pH 7.0 (C) and with the addition of 30% TFE. (B) CD spectra of peptides 12/1Ser, 12/1Thr, 12/1Ala, 12/1Asn
and 12/1 in in 5 mM Sodium Phosphate buffer pH 7.0 and (D) with the addition of 30% TFE.
doi:10.1371/journal.pone.0024122.g002
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interacts with a negatively charged region on the MDM2 surface
(Figure 3) which increases the electrostatic component of the
interaction between 12/1 and MDM2 thus making any
conformational change energetically expensive.
Two distinct thermodynamic systems of interactions
between p53 and 12/1 based peptides with the MDM2
N-terminus
The major difference between the two groups of peptides is that
the DHbinding for the p53 peptide family members (Table 1) ranges
Figure 3. Representative snapshots depicting helix formation in the MDM2 interacting derivative peptides and their packing
against the surface of MDM2. Representative snapshots to show that non-Proline substitution at the C-terminal end of the ligand promotes helix
formation. Also shown is that the bulkier Asn side chain is accommodated differently compared to a smaller side chain like Ser when the peptide is in
a helical conformation. The positively and negatively charged regions on the MDM2 surface have been shown with blue and red colors respectively.
doi:10.1371/journal.pone.0024122.g003
Figure 4. Representative snapshots from the computer simulations of the p53 family based peptides and their interactions with
MDM2. Representative snapshots from the trajectories of MDM2 complexed with the p53 mutants: (A) P27S (B) P27A (C) P27T and (D) P27T. Two
different snapshots have been shown of P27T to show significantly different interactions.
doi:10.1371/journal.pone.0024122.g004
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peptide group it ranges between 27.1 kcal/mol and 210.8 kcal/
mol. The 12/1 group is enthalpically driven compared to the p53
group (see Table 1 for ITC data), although the conformations of
the two groups in their complexed states are largely similar; this
trend is also mirrored in the computations. The different
enthalpies may originate, at least partly, in the observation that
there appears to be greater electrostatic complementarity between
the 12/1 peptides and MDM2 (see Figure 5) and also in the total
electrostatic energies of the complexes which are about 15%
stronger for the 12/1 peptide-MDM2 complex.
In the 12/1 series, while residue M1 does not form any specific
interactions with MDM2, residue M5 forms favourable van der
Waals interactions with the M62 (MDM2) side chain (Figure 6). In
p53, the equivalent position is occupied by S20 which cannot
optimally pack with M62 and form such favourable hydrophobic
interactions. In the 12/1 peptide, if this region is modeled as a
helix (a representative snapshot was taken from the trajectory to
model the residues M1-R3 as a-helical followed by some energy
minimization) the interactions of R3 with the MDM2 are retained
but a new cluster of van der Waals interactions are formed by the
M1 and M5 residues of the peptide with M62 of MDM2 (Figure 6).
The helical conformation described was not accessed during the
20 ns MD simulation and suggests that much longer timescales are
needed for these transitions.
Substitution of the C-terminal residue modulates the
energy of binding of the MDM2 interacting peptides
For both groups of peptides, modulation of the free energy is
determined by the type of substitution at the C-terminal residue.
However the mechanism by which this modulation occurs in both
groups shares several similarities. The Ser and Thr mutant peptides
which are more helical in the CD data (Figure 2) have much higher
entropic benefits when binding to MDM2. However, the 12/1Ala
derivative does not undergo an entropically favourable interaction
with MDM2. This may arise from increased fluctuations in the
bound state. The higher helicity of the 12/1Ser and 12/1Thr
peptidesreducestheentropiccostupontransitionfromuncomplexed
to MDM2-complexed states. Simulations show (see Figure7)thatthe
Ser side chain makes the peptide more prone to forming a helix by
forming a hydrogen bond with the backbone of W23 (and also
occasionally with the side chain NH of W23). The Thr substitution
also appears to increase helicity via this mechanism (see Figure 7).
This mechanism also applies to the Ser and Thr derivatives in the
p53 family. Interestingly in the 12/1 family the Thr peptide has
higher helical propensity, despite the presence of a methyl group
which should interfere with the intrahelical hydrogen bonding.
However the observed difference in helicity is probably due to the
effect of the different peptide sequences and local packing effects.
The p53Ala and 12/1Ala derivative peptides behave differently
to the Thr/Ser derivative peptides in the MD simulations with the
C-terminal part of the Ala derivative peptides not undergoing a
transition from the extended conformation to a helical confirma-
tion during the simulation. In general Ala is helix promoting and
has a very high helical propensity. However with Ala located at the
C-terminus (N12A of 12/1 and P27A for p53) its effects on the
local secondary structure of the peptide are reduced. It cannot
form a hydrogen bond to W23/W8 (p53 and 12/1 peptides
respectively) in the manner that Ser/Thr residues do. However if
the C-terminal section of the Ala derivative peptide is modeled
initially as a-helix then a 10 ns MD shows that it remains stable
there. The helical conformation places the Ala residue in the
vicinity of a highly polar environment on the surface of MDM2.
The 12/1Ala has appears to stable in both situations, contributing
251.1 kcal/mol (extended) and 258 kcal/mol (helix) of the total
stabilization energy [Emm(Total)] from MMGBSA calculations.
The larger stability of the helical conformation arises from larger
hydrophobic packing. Therefore the transition of the C-terminal
region of the Ala derivative peptide from an extended to a helical
conformation may be characterized by a larger energy barrier,
and this may explain the lack of a spontaneous transition as
observed for the other peptides.
Figure 5. Snapshot showing packing of the p53WT and 12/1 against an electrostatic surface representation of the MDM2. A) Diagram
shows the packing of p53WT peptide against an electrostatic surface representation of MDM2 (blue corresponds to positive and red to negative). B)
Diagram shows that the 12/1 peptide packs against MDM2 with better electrostatic complementarity.
doi:10.1371/journal.pone.0024122.g005
C-Terminal Modulation of MDM2 Binding Peptides
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e24122According to the Chow Fasman scale, residues W23 to L26 in
the p53 template peptide are all helix promoting. However, the
presence of G10 (equivalent to L25 of p53) in the 12/1 peptide
family drastically reduces the helical propensity and incorporates
flexibility that in turn enables the C-terminus of 12/1Ala to
remain in an extended conformation. It is this flexibility that
allows the 12/1 family based peptides to pack more optimally
against MDM2 and which is reflected overall by higher enthalpies
of binding. This flexibility allows the C-terminal Ala to pack
optimally against MDM2 (See Figure 7 and Movies S1). The
extended conformation of the 12/1 derivative peptide encourages
the formation of a salt bridge between E9-K51 and this is reflected
in the much higher enthalpic gain upon complex formation (see
Figure 7f). However the peptide simulations, with C-terminal
region of 12/1Ala initially modeled as a helix, shows that the C-
terminal region of the peptide remains stable as a helix throughout
the simulation. The salt bridge between E9 and K51 is lost due to
a larger spatial distance, but it seems that the structure tolerates
the loss of the salt bridge, compensated for by the hydrophobic
packing of the Ala residue.
The 12/1 peptide family also contains a Y (helix propensity
0.69) at position 7, which along with the glycine at position 10,
causes the peptide to be more flexible and as a result enhances the
entropic difference between the uncomplexed and complexed
states of the peptide. This is in agreement with the observation that
the 12/1 peptide group has a less favourable entropic component
in their interactions with MDM2.
For the proline derivative peptides the simulations show that
they interact with MDM2 in an extended conformation at the C-
terminus. However due to the higher flexibility of the 12/1Pro
peptide the P12 residue is able to form stacking interactions with
the Y100 ring (see Figure 8) that are not observed in the p53WT
peptide. In the p53WT peptide there is still a tendency to form this
interaction but due to the higher rigidity imposed by the helix
favoring L25 and L26 residues the P27 and Y100 ring do not
optimally pack against each other. For this reason the N12P
mutation in 12/1Pro causes a decrease in the DH that seems to
more than compensate for the loss of packing in the helical 12/1
peptide (which has N at position 12) and the change of orientation
in Y100. However the Pro to Asn change in the p53 peptide family
causes the peptide to pack more tightly and efficiently against
MDM2, which leads to the slight enthalpic gain.
Discussion
The N-terminus of MDM2 exhibits conformational plasticity
that allows it to accommodate peptides in several different
orientations. Recent papers have reported the discovery and
development of peptides with nanomolar affinities that interact
with MDM2 and also bind tightly to MDM4. Our studies have
focused on the mechanism by which these peptides interact with
MDM2 and how these peptides can be converted from the low
micromolar and high nanomolar binding affinities to much more
potent binding entities. Interestingly this conversion can be
engineered by a simple mutation of the C-terminal residue in a
12 mer peptide to either a Thr, Ser or Ala. However intriguingly a
destabilizing Pro at the C-terminus of the p53 peptide appears to
lose the destabilization in the 12/1 peptide sequence, thus
highlighting the importance of the context in which the mutation
is made. This, together with differences in the helical propensities
of a series of C-terminal mutants of the two peptides has
demonstrated the existence of two distinct modes of interactions.
One mode is much more enthalpically driven and correlates with
peptides that have a lower helical propensity (the 12/1 family) and
the other mode is more entropically driven and correlates with
peptides that are more helical in nature (the p53 family). This
makes sense since the p53 family has more preformed helical
motifs in solution that reduces the entropic penalty upon
sequestration by MDM2 while the 12/1 peptides are more flexible
and hence ‘‘morph’’ better into the surface of MDM2, enhancing
the enthalpic gains [24]. Molecular dynamics simulations suggest
that the high affinity binders of both peptide families gravitate
towards forming a stable C-terminal helix when bound to MDM2.
These conformations are characterized by helical motifs that are
associated with high affinity and the Y100-in state (Y100 points in
towards the binding cavity). In contrast, peptides that prefer to
form an extended C-terminal strand are characterized by the
Y100-out state and have a lower affinity. These observations
highlight that two distinct thermodynamic modes of interactions
can be engineered to create more potent peptides via similar
substitutions. However exceptions such as the effect of the
inhibitory Pro in the p53 Wt sequence compared to its lack of
effect on the 12/1 peptide highlight the complex and subtle
interplay that is associated with the mutual modulation of the
peptides and the protein surface.
The general consensus is that preorganizing a ligand into its
bound conformation will reduce the entropic penalty upon
binding, and is borne out generally in our system. But the picture
may be far more complex than the simplistic two-state paradigm.
First of all, a question arises as to the nature of helicity and its
assumption in this process. CD spectroscopy tells us that these
peptides assume helical conformations in solution. But what is not
known is how different are these helices between the free and
bound states and how much the protein and peptides modulate
each other on binding [21,25]. Our own thermodynamic data is
chacaterized by several puzzling features. Why is it that in the p53
family peptides, the Ser, Thr, Asn and Ala mutants display helicity
Figure 6. 12/1 peptide has the potential to form extra packing
interactions with MDM2. (A) The equivalent position of S20 of the
p53 family has been replaced by M5 in the 12/1 peptide family. Residue
M5 packs much more favorably against M62 of MDM2 than the S20
residue in the p53 based peptides. (B) If the first three residues of the
12/1 family are modeled as a helix, even though this was not observed
in the simulation, the M1 residues would also pack favorably against the
M5 12/1 residue of 12/1 and the M62 residue of MDM2.
doi:10.1371/journal.pone.0024122.g006
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unfavourable while that of the other two very favourable. The
answer lies partly in the fact that entropic changes involve many
factors that simulations and even experiments are unable to
account for. These factors can include the displacement of
interfacial/buried water molecules (estimated to contribute up to
2 kcal/mol/water) [26,27], burial of a water molecule [28]
(estimated to contribute up to 1 kcal/mol) or increase in the
conformational entropy of the complex [29]. The resolution of the
current simulations did not enable us to succeed in computing
differences that could provide a statistically robust mechanism
behind the observed changes in entropy. Indeed, parameters such
as fluctuation differences for example did not reveal any significant
correlations, nor did analysis of hydration. In a detailed study
combining NMR and simulations [30] the authors conclude that
binding energetic differences between peptides to the same
Figure 7. Representative snapshots from the trajectories of 12/1 mutant peptides complexed with MDM2. Snapshots from the
trajectories of 12/1 mutant peptides complexed with MDM2. The (A) N12S, (B) N12T and (C) N12A MD simulations were started with a modeled helix
at the C-terminus. Figures 7D) to 7G) show different orientations of the C-terminus of the N12A 12/1 mutant at different time points of the MD
simulation trajectory (also see Movies S1).
doi:10.1371/journal.pone.0024122.g007
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hydration effects, that are really not readily quantifiable by
simulations or experiment; some progress is being made [27].
Nevertheless, visual examination of the simulations provide some
explanation. Upon complexation, the Asn mutant adopts a
conformation that is extended at the C-terminus compared to
that adopted by Ser/Thr. This clearly suggests that the Asn
mutant goes from an unbound helical state to an extended state
when bound and could account for the opposite trend in entropy
even as it makes more enthalpic gains in the extended state. Of
course it is not clear what the extent of helicity is in the bound
state, given the resolution of CD spectroscopy and whether a small
extension at the C-terminus in the unbound state will be detectable
or not. Also it is likely that there are subtle changes in hydration at
the C-terminus between the Asn and the Ser/Thr systems. In the
case of Ser, Thr and Ala, the peptide is helical in the bound state
and thus may result in the release of waters that would be
embedded in the extended state, which is the case of Asn.
However, the wild type is extended too and yet undergoes a large
entropic gain. Close inspection reveals that while the Pro in the
wild type enables the extended conformation of the C-terminus of
p53 to stick to the side of MDM2, thus leading to an increase in
the entropy of the bound state [11], the extended C-terminus in
Asn does not stick to the surface but instead ‘‘hovers embedded in
the cleft and interacts with the N-terminus of MDM2. This leads
to the higher enthalpy and at the same time compacts the structure
of the complex possibly leading to a decrease in the entropy.
Indeed, local packing effects can have subtle origins and yet
dramatic effects as was evidenced in a study where the mere
change of an amino acid in a peptide from Thr to Ser renders the
FHA domain incapable of recognizing the peptide [31]. In
conclusion, the current work further dissects and highlights the
subtle nature of protein-peptide interactions through a study of the
interactions between the N-terminal domains of MDM2 and
‘‘designed’’ p53 peptides, and we hope our findings will further
stimulate enquiry and the design of peptidomimetic molecules with
more ‘‘rational’’ insights.
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